EMERZENE

Main Focus
Gene Editing, Pain Relief, Non-addictive Opiates

Company Stage
Pre-clinical

Disease Focus
Cancer, Pain management

Technology | Tool
CRISPR, ZFN'S

Funding Stage
SEED

Location
DUBLIN, CALIFORNIA

Website
https://www.emerzenetx.com

Pipeline
https://www.emerzenetx.com

Partners
MERCK, NIST

EMERZENE

Your Latest CMN News

Appetite for Destruction: The Indiscriminate...

Mar. 27, 2023

Researchers from Utah State University and Germany’s Helmholtz Institute for RNA-based Infection Research demonstrate that upon recognition of an RNA...

CMN Weekly (24 March 2023) - Your Weekly CRISPR...

Mar. 24, 2023

Some of the best links we picked up around the internet

Webinar

Enhancing T Cell Function for Cancer immunotherapy...

Mar. 20, 2023

Read more about the webinar - Enhancing T Cell Function for Cancer immunotherapy With CRISPR

CMN Weekly (17 March 2023) - Your Weekly CRISPR...

Mar. 17, 2023

Some of the best links we picked up around the internet

Intellia Therapeutics Gets FDA Green Light to...

Mar. 15, 2023

Intellia Therapeutics recently announced that the FDA has cleared an Investigational New Drug application for NTLA-2002, a single-dose in vivo CRISPR...

CMN Weekly (10 March 2023) - Your Weekly CRISPR...

Mar. 10, 2023

Some of the best links we picked up around the internet

EMERZENE

Tags

Related News and Updates

Job Opportunities

Clinical Trials

Pre-clinical Trials

Stocks and Markets

Diseases

Webinar

Your Latest CMN News